Eisai Korea Inc. clinical trials

A country office of Eisai Co., Ltd.

The registry lists 31 studies whose lead sponsor is Eisai Korea Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 6, 2026.

Studies

Recruiting first, then most recently updated. Showing 31 of 31. All Eisai Co., Ltd. studies →

• A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean ParticipantsRecruitingNCT06246123

  Sponsor listed in the registry: Eisai Korea Inc.

• A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's DiseaseRecruitingNCT06810960

  Sponsor listed in the registry: Eisai Korea Inc.

• A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical PracticeActive, not recruitingNCT06964113Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• A Study of Filgotinib in Korean Participants With Rheumatoid ArthritisCompletedNCT06625242Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)CompletedNCT05225324

  Sponsor listed in the registry: Eisai Korea Inc.

• A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic SeizuresCompletedNCT05533814Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South KoreaCompletedNCT05312632Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• A Study of Lenvatinib in Combination With Pembrolizumab in Korean PatientsCompletedNCT05375136

  Sponsor listed in the registry: Eisai Korea Inc.

• A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) ParticipantsCompletedNCT05225207

  Sponsor listed in the registry: Eisai Korea Inc.

• A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal UlcerCompletedNCT05208268

  Sponsor listed in the registry: Eisai Korea Inc.

• A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple SclerosisCompletedNCT05366036

  Sponsor listed in the registry: Eisai Korea Inc.

• Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial EpilepsyCompletedNCT01140867Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's DiseaseCompletedNCT00381381Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety EvaluationCompletedNCT01127256Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• Alzheimer's Disease Long-term Follow-up Study (ALF Study)CompletedNCT00165724Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• Post-Marketing Surveillance of Lenvima in Korean PatientsCompletedNCT02764554

  Sponsor listed in the registry: Eisai Korea Inc.

• A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World SettingCompletedNCT03448445

  Sponsor listed in the registry: Eisai Korea Inc.

• A Study of Fycompa (Perampanel) in Korean ParticipantsCompletedNCT02722590

  Sponsor listed in the registry: Eisai Korea Inc.

• Symbenda Post-Marketing Surveillance (PMS)CompletedNCT02434484

  Sponsor listed in the registry: Eisai Korea Inc.

• Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real WorldCompletedNCT03264703

  Sponsor listed in the registry: Eisai Korea Inc.

• Halaven Post-Marketing Surveillance (PMS)CompletedNCT02441764

  Sponsor listed in the registry: Eisai Korea Inc.

• Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD PatientsCompletedNCT03264690

  Sponsor listed in the registry: Eisai Korea Inc.

• Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary GeneralizationCompletedNCT02726074Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer ParticipantsCompletedNCT03437083

  Sponsor listed in the registry: Eisai Korea Inc.

• A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease PatientsCompletedNCT02158910

  Sponsor listed in the registry: Eisai Korea Inc.

• A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)CompletedNCT02262975

  Sponsor listed in the registry: Eisai Korea Inc.

• Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast CancerCompletedNCT01961544Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's DiseaseCompletedNCT02097056Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD PatientsTerminatedNCT00165750Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• Low and High Dose Zonisamide in Children as MonotherapyCompletedNCT01127165Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.

• A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated EpilepsiesCompletedNCT00154076Phase 4

  Sponsor listed in the registry: Eisai Korea Inc.